Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


Oliena Studio

Stroke and language recovery: 9000+ videos

EspañolItalianoSarduEnglish | PDF+


  Malaria

  Free Subscription


Articles published in Vaccine

Retrieve available abstracts of 41 articles:
HTML format
Text format



Single Articles


    January 2019
  1. COELHO CH, Gazzinelli-Guimaraes PH, Howard J, Barnafo E, et al
    Chronic helminth infection does not impair immune response to malaria transmission blocking vaccine Pfs230D1-EPA/Alhydrogel(R) in mice.
    Vaccine. 2019 Jan 23. pii: S0264-410X(19)30090.
    PubMed     Text format     Abstract available


  2. HEALY SA, Fried M, Richie T, Bok K, et al
    Malaria vaccine trials in pregnant women: An imperative without precedent.
    Vaccine. 2019 Jan 6. pii: S0264-410X(18)31698.
    PubMed     Text format     Abstract available


    October 2018
  3. KANOI BN, Nagaoka H, Morita M, White MT, et al
    Comprehensive analysis of antibody responses to Plasmodium falciparum erythrocyte membrane protein 1 domains.
    Vaccine. 2018;36:6826-6833.
    PubMed     Text format     Abstract available


    August 2018
  4. CHICHESTER JA, Green BJ, Jones RM, Shoji Y, et al
    Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Vaccine. 2018 Aug 17. pii: S0264-410X(18)31159.
    PubMed     Text format     Abstract available


    June 2018
  5. PANDEY RK, Ali M, Ojha R, Bhatt TK, et al
    Development of multi-epitope driven subunit vaccine in secretory and membrane protein of Plasmodium falciparum to convey protection against malaria infection.
    Vaccine. 2018 Jun 16. pii: S0264-410X(18)30748.
    PubMed     Text format     Abstract available


    April 2018
  6. AN SJ, Scaria PV, Chen B, Barnafo E, et al
    Development of a bivalent conjugate vaccine candidate against malaria transmission and typhoid fever.
    Vaccine. 2018 Apr 19. pii: S0264-410X(18)30518.
    PubMed     Text format     Abstract available


  7. FONSECA JA, McCaffery JN, Caceres J, Kashentseva E, et al
    Inclusion of the murine IgGkappa signal peptide increases the cellular immunogenicity of a simian adenoviral vectored Plasmodium vivax multistage vaccine.
    Vaccine. 2018 Apr 12. pii: S0264-410X(18)30474.
    PubMed     Text format     Abstract available


    March 2018
  8. NLINWE ON, Kusi KA, Adu B, Sedegah M, et al
    T-cell responses against Malaria: Effect of parasite antigen diversity and relevance for vaccine development.
    Vaccine. 2018 Mar 21. pii: S0264-410X(18)30368.
    PubMed     Text format     Abstract available


    February 2018
  9. SIMON N, Friedrich O, Kappes B
    Quantification of human complement factor H binding to asexual malaria blood stages by an enzyme-linked immunosorbent assay.
    Vaccine. 2018 Feb 12. pii: S0264-410X(18)30153.
    PubMed     Text format     Abstract available


  10. NIELSEN CM, Vekemans J, Lievens M, Kester KE, et al
    RTS,S malaria vaccine efficacy and immunogenicity during Plasmodium falciparum challenge is associated with HLA genotype.
    Vaccine. 2018 Feb 10. pii: S0264-410X(18)30142.
    PubMed     Text format     Abstract available


    December 2017
  11. KABA SA, Karch CP, Seth L, Ferlez KMB, et al
    Self-assembling protein nanoparticles with built-in flagellin domains increases protective efficacy of a Plasmodium falciparum based vaccine.
    Vaccine. 2017 Dec 18. pii: S0264-410X(17)31728.
    PubMed     Text format     Abstract available


    November 2017
  12. ROESTENBERG M, Mordmuller B, Ockenhouse C, Mo A, et al
    The frontline of controlled human malaria infections: A report from the controlled human infection models Workshop in Leiden University Medical Centre 5 May 2016.
    Vaccine. 2017 Nov 16. pii: S0264-410X(17)31522.
    PubMed     Text format     Abstract available


    October 2017
  13. SHIRATSUCHI T, Rai U, Kaneko I, Zhang M, et al
    A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.
    Vaccine. 2017 Oct 28. pii: S0264-410X(17)31474.
    PubMed     Text format     Abstract available


  14. PERRAUT R, Varela ML, Joos C, Diouf B, et al
    Association of antibodies to Plasmodium falciparum merozoite surface protein-4 with protection against clinical malaria.
    Vaccine. 2017 Oct 14. pii: S0264-410X(17)31391.
    PubMed     Text format     Abstract available


    September 2017
  15. SIRIMA SB, Durier C, Kara L, Houard S, et al
    Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel(R) in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Vaccine. 2017 Sep 22. pii: S0264-410X(17)31247.
    PubMed     Text format     Abstract available


  16. VENKATRAMAN N, Anagnostou N, Bliss C, Bowyer G, et al
    Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M.
    Vaccine. 2017 Sep 20. pii: S0264-410X(17)31248.
    PubMed     Text format     Abstract available


    June 2017
  17. GENITO CJ, Beck Z, Phares TW, Kalle F, et al
    Liposomes containing monophosphoryl lipid A and QS-21 serve as an effective adjuvant for soluble circumsporozoite protein malaria vaccine FMP013.
    Vaccine. 2017 Jun 5. pii: S0264-410X(17)30729.
    PubMed     Text format     Abstract available


    May 2017
  18. SINGH SK, Thrane S, Janitzek CM, Nielsen MA, et al
    Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Vaccine. 2017 May 31. pii: S0264-410X(17)30690.
    PubMed     Text format     Abstract available


  19. ZHU D, Wu Y, McClellan H, Dai W, et al
    Accelerated and long term stability study of Pfs25-EPA conjugates adjuvanted with Alhydrogel(R).
    Vaccine. 2017;35:3232-3238.
    PubMed     Text format     Abstract available


  20. GBEDANDE K, Fievet N, Viwami F, Ezinmegnon S, et al
    Clinical development of a VAR2CSA-based placental malaria vaccine PAMVAC: Quantifying vaccine antigen-specific memory B & T cell activity in Beninese primigravidae.
    Vaccine. 2017 May 17. pii: S0264-410X(17)30635.
    PubMed     Text format     Abstract available


  21. FONSECA JA, McCaffery JN, Kashentseva E, Singh B, et al
    A prime-boost immunization regimen based on a simian adenovirus 36 vectored multi-stage malaria vaccine induces protective immunity in mice.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30554.
    PubMed     Text format     Abstract available


  22. LI X, Huang J, Kawamura A, Funakoshi R, et al
    Co-localization of a CD1d-binding glycolipid with an adenovirus-based malaria vaccine for a potent adjuvant effect.
    Vaccine. 2017 May 5. pii: S0264-410X(17)30578.
    PubMed     Text format     Abstract available


    April 2017
  23. CHATTOPADHYAY R, Pratt D
    Role of controlled human malaria infection (CHMI) in malaria vaccine development: A U.S. food & drug administration (FDA) perspective.
    Vaccine. 2017 Apr 18. pii: S0264-410X(17)30406.
    PubMed     Text format    



  24. Malaria vaccine: WHO position paper, January 2016 - Recommendations.
    Vaccine. 2017 Apr 3. pii: S0264-410X(16)30982.
    PubMed     Text format     Abstract available


    March 2017
  25. LUO K, Zavala F, Gordy J, Zhang H, et al
    Extended protection capabilities of an immature dendritic-cell targeting malaria sporozoite vaccine.
    Vaccine. 2017 Mar 22. pii: S0264-410X(17)30369.
    PubMed     Text format     Abstract available


  26. FORD T, Wenden C, Mbekeani A, Dally L, et al
    Cryopreservation-related loss of antigen-specific IFNgamma producing CD4+ T-cells can skew immunogenicity data in vaccine trials: Lessons from a malaria vaccine trial substudy.
    Vaccine. 2017 Mar 9. pii: S0264-410X(17)30241.
    PubMed     Text format     Abstract available


  27. SETH L, Bingham Ferlez KM, Kaba SA, Musser DM, et al
    Development of a self-assembling protein nanoparticle vaccine targeting Plasmodium falciparum Circumsporozoite Protein delivered in three Army Liposome Formulation adjuvants.
    Vaccine. 2017 Mar 5. pii: S0264-410X(17)30243.
    PubMed     Text format     Abstract available


    January 2017
  28. ANDERSSON AC, Resende M, Salanti A, Nielsen MA, et al
    Novel adenovirus encoded virus-like particles displaying the placental malaria associated VAR2CSA antigen.
    Vaccine. 2017 Jan 25. pii: S0264-410X(17)30033.
    PubMed     Text format     Abstract available


  29. KANOI BN, Takashima E, Morita M, White MT, et al
    Antibody profiles to wheat germ cell-free system synthesized Plasmodium falciparum proteins correlate with protection from symptomatic malaria in Uganda.
    Vaccine. 2017 Jan 12. pii: S0264-410X(17)30003.
    PubMed     Text format     Abstract available


  30. MILLIGAN P, Flach C, Theisen M
    Efficacy of the GMZ2 malaria vaccine in African children.
    Vaccine. 2017;35:202.
    PubMed     Text format    


  31. EJIGU DA
    When should a time at risk start in efficacy malaria vaccine trials?
    Vaccine. 2017;35:201.
    PubMed     Text format    


  32. GESSNER BD, Knobel DL, Conan A, Finn A, et al
    Could the RTS,S/AS01 meningitis safety signal really be a protective effect of rabies vaccine?
    Vaccine. 2017 Jan 5. pii: S0264-410X(17)30001.
    PubMed     Text format     Abstract available


    December 2016
  33. MATTHIESSEN L, Lang H, Klimathianaki M, Hanrahan F, et al
    European strategy for vaccine development against infectious diseases.
    Vaccine. 2016 Dec 22. pii: S0264-410X(16)30952.
    PubMed     Text format     Abstract available


  34. PEHRSON C, Heno KK, Adams Y, Resende M, et al
    Comparison of functional assays used in the clinical development of a placental malaria vaccine.
    Vaccine. 2016 Dec 21. pii: S0264-410X(16)31235.
    PubMed     Text format     Abstract available


    November 2016
  35. DATTA D, Bansal GP, Gerloff DL, Ellefsen B, et al
    Immunogenicity and malaria transmission reducing potency of Pfs48/45 and Pfs25 encoded by DNA vaccines administered by intramuscular electroporation.
    Vaccine. 2016 Nov 29. pii: S0264-410X(16)31143.
    PubMed     Text format     Abstract available


  36. GALACTIONOVA K, Tediosi F, Camponovo F, Smith TA, et al
    Country specific predictions of the cost-effectiveness of malaria vaccine RTS,S/AS01 in endemic Africa.
    Vaccine. 2016 Nov 24. pii: S0264-410X(16)31103.
    PubMed     Text format     Abstract available


    October 2016
  37. BRICKLEY EB, Coulibaly M, Gabriel EE, Healy SA, et al
    Utilizing direct skin feeding assays for development of vaccines that interrupt malaria transmission: A systematic review of methods and case study.
    Vaccine. 2016 Oct 24. pii: S0264-410X(16)30945.
    PubMed     Text format     Abstract available


    September 2016
  38. SPEARMAN P, Mulligan M, Anderson EJ, Shane AL, et al
    A phase 1, randomized, controlled dose-escalation study of EP-1300 polyepitope DNA vaccine against Plasmodium falciparum malaria administered via electroporation.
    Vaccine. 2016 Sep 30. pii: S0264-410X(16)30855.
    PubMed     Text format     Abstract available


  39. NTEGE EH, Arisue N, Ito D, Hasegawa T, et al
    Identification of Plasmodium falciparum reticulocyte binding protein homologue 5-interacting protein, PfRipr, as a highly conserved blood-stage malaria vaccine candidate.
    Vaccine. 2016 Sep 28. pii: S0264-410X(16)30841.
    PubMed     Text format     Abstract available


    May 2016
  40. BLAGBOROUGH AM, Musiychuk K, Bi H, Jones RM, et al
    Transmission blocking potency and immunogenicity of a plant-produced Pvs25-based subunit vaccine against Plasmodium vivax.
    Vaccine. 2016 May 10. pii: S0264-410X(16)30290.
    PubMed     Text format     Abstract available


    March 2016
  41. BALDWIN SL, Roeffen W, Singh SK, Tiendrebeogo RW, et al
    Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
    Vaccine. 2016 Mar 16. pii: S0264-410X(16)00327.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malaria is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: